Equities analysts predict that Strongbridge Biopharma plc (NASDAQ:SBBP) will announce sales of $5.48 million for the current quarter, Zacks reports. Four analysts have provided estimates for Strongbridge Biopharma’s earnings, with the highest sales estimate coming in at $5.99 million and the lowest estimate coming in at $4.90 million. Strongbridge Biopharma posted sales of $2.53 million in the same quarter last year, which would indicate a positive year over year growth rate of 116.6%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Strongbridge Biopharma will report full-year sales of $20.30 million for the current year, with estimates ranging from $18.65 million to $21.81 million. For the next year, analysts anticipate that the firm will report sales of $45.06 million, with estimates ranging from $27.85 million to $59.75 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.41. The business had revenue of $4.30 million during the quarter, compared to analysts’ expectations of $4.53 million.
SBBP traded down $0.14 during midday trading on Thursday, hitting $4.41. The company’s stock had a trading volume of 166,232 shares, compared to its average volume of 344,542. The company has a debt-to-equity ratio of 8.76, a quick ratio of 6.38 and a current ratio of 6.46. Strongbridge Biopharma has a 52-week low of $3.85 and a 52-week high of $9.25.
In other news, major shareholder Associates L.L.C. Cdk bought 360,995 shares of the firm’s stock in a transaction that occurred on Wednesday, August 8th. The stock was purchased at an average cost of $4.93 per share, for a total transaction of $1,779,705.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 4.20% of the company’s stock.
A number of large investors have recently bought and sold shares of SBBP. Laurion Capital Management LP purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at $101,000. Dynamic Technology Lab Private Ltd purchased a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $110,000. Cubist Systematic Strategies LLC purchased a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $130,000. Jane Street Group LLC purchased a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $154,000. Finally, Citadel Advisors LLC purchased a new stake in Strongbridge Biopharma in the 1st quarter valued at about $166,000. Institutional investors own 67.24% of the company’s stock.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
See Also: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.